40 related articles for article (PubMed ID: 15749420)
1. The effect of cyclin D expression on cell proliferation in human gliomas.
Zhang X; Zhao M; Huang AY; Fei Z; Zhang W; Wang XL
J Clin Neurosci; 2005 Feb; 12(2):166-8. PubMed ID: 15749420
[TBL] [Abstract][Full Text] [Related]
2. Cyclin D1 expression in gliomas.
Cavalla P; Dutto A; Piva R; Richiardi P; Grosso R; Schiffer D
Acta Neuropathol; 1998 Feb; 95(2):131-5. PubMed ID: 9498046
[TBL] [Abstract][Full Text] [Related]
3. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.
Zhao S; Lin Y; Xu W; Jiang W; Zha Z; Wang P; Yu W; Li Z; Gong L; Peng Y; Ding J; Lei Q; Guan KL; Xiong Y
Science; 2009 Apr; 324(5924):261-5. PubMed ID: 19359588
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of cyclin D1 inhibits proliferation, induces apoptosis, and attenuates the invasive capacity of human glioblastoma cells.
Wang J; Wang Q; Cui Y; Liu ZY; Zhao W; Wang CL; Dong Y; Hou L; Hu G; Luo C; Chen J; Lu Y
J Neurooncol; 2012 Feb; 106(3):473-84. PubMed ID: 21912938
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities.
Cairns RA; Mak TW
Cancer Discov; 2013 Jul; 3(7):730-41. PubMed ID: 23796461
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.
Takano S; Kato Y; Yamamoto T; Kaneko MK; Ishikawa E; Tsujimoto Y; Matsuda M; Nakai K; Yanagiya R; Morita S; Tsuboi K; Matsumura A
J Neurooncol; 2012 Jul; 108(3):361-73. PubMed ID: 22396072
[TBL] [Abstract][Full Text] [Related]
7. Glioma diagnosis: immunohistochemistry and beyond.
Dunbar E; Yachnis AT
Adv Anat Pathol; 2010 May; 17(3):187-201. PubMed ID: 20418673
[TBL] [Abstract][Full Text] [Related]
8. CAP-RNAseq: an integrated pipeline for functional annotation and prioritization of co-expression clusters.
Vural-Ozdeniz M; Calisir K; Acar R; Yavuz A; Ozgur MM; Dalgıc E; Konu O
Brief Bioinform; 2024 Jan; 25(2):. PubMed ID: 38279653
[TBL] [Abstract][Full Text] [Related]
9. Tasmanian devil cathelicidins exhibit anticancer activity against Devil Facial Tumour Disease (DFTD) cells.
Petrohilos C; Patchett A; Hogg CJ; Belov K; Peel E
Sci Rep; 2023 Aug; 13(1):12698. PubMed ID: 37542170
[TBL] [Abstract][Full Text] [Related]
10. Clinical Correlation and Role of Cyclin D1 Expression in Glioblastoma Patients: A Study From North India.
Jaiswal M; Tripathi A; Singh D; Kumar A; Singh M; Batra N; Verma A
Cureus; 2022 Feb; 14(2):e22346. PubMed ID: 35223330
[TBL] [Abstract][Full Text] [Related]
11. hTERT Transduction Extends the Lifespan of Primary Pediatric Low-Grade Glioma Cells While Preserving the Biological Response to NGF.
Franzese O; Di Francesco AM; Meco D; Graziani G; Cusano G; Levati L; Riccardi R; Ruggiero A
Pathol Oncol Res; 2021; 27():612375. PubMed ID: 34257579
[TBL] [Abstract][Full Text] [Related]
12. An Immunohistochemical Study of Cyclin D1 Expression in Astrocytic Tumors and its Correlation with Tumor Grade.
Mahzouni P; Taheri F
Iran J Pathol; 2019; 14(3):252-257. PubMed ID: 31583003
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of glioblastoma stem cell markers OLIG2 and CCND2.
Bouchart C; Trépant AL; Hein M; Van Gestel D; Demetter P
Cancer Med; 2020 Feb; 9(3):1069-1078. PubMed ID: 31568682
[TBL] [Abstract][Full Text] [Related]
14. Generation of a PAX6 knockout glioblastoma cell line with changes in cell cycle distribution and sensitivity to oxidative stress.
Hegge B; Sjøttem E; Mikkola I
BMC Cancer; 2018 May; 18(1):496. PubMed ID: 29716531
[TBL] [Abstract][Full Text] [Related]
15. Impact of 9p deletion and p16, Cyclin D1, and Myc hyperexpression on the outcome of anaplastic oligodendrogliomas.
Michaud K; de Tayrac M; D'Astous M; Paquet C; Gould PV; Saikali S
PLoS One; 2018; 13(2):e0193213. PubMed ID: 29489901
[TBL] [Abstract][Full Text] [Related]
16. CRNDE Promotes Malignant Progression of Glioma by Attenuating miR-384/PIWIL4/STAT3 Axis.
Zheng J; Liu X; Wang P; Xue Y; Ma J; Qu C; Liu Y
Mol Ther; 2016 Aug; 24(7):1199-1215. PubMed ID: 27058823
[TBL] [Abstract][Full Text] [Related]
17. Prioritization of anticancer drugs against a cancer using genomic features of cancer cells: A step towards personalized medicine.
Gupta S; Chaudhary K; Kumar R; Gautam A; Nanda JS; Dhanda SK; Brahmachari SK; Raghava GP
Sci Rep; 2016 Mar; 6():23857. PubMed ID: 27030518
[TBL] [Abstract][Full Text] [Related]
18. WWOX suppresses prostate cancer cell progression through cyclin D1-mediated cell cycle arrest in the G1 phase.
Lin JT; Li HY; Chang NS; Lin CH; Chen YC; Lu PJ
Cell Cycle; 2015; 14(3):408-16. PubMed ID: 25659037
[TBL] [Abstract][Full Text] [Related]
19. LEF1 regulates glioblastoma cell proliferation, migration, invasion, and cancer stem-like cell self-renewal.
Gao X; Mi Y; Ma Y; Jin W
Tumour Biol; 2014 Nov; 35(11):11505-11. PubMed ID: 25128061
[TBL] [Abstract][Full Text] [Related]
20. Structural and logical analysis of a comprehensive hedgehog signaling pathway to identify alternative drug targets for glioma, colon and pancreatic cancer.
Chowdhury S; Pradhan RN; Sarkar RR
PLoS One; 2013; 8(7):e69132. PubMed ID: 23935937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
